Management of nasopharyngeal carcinoma: ESMO-EURACAN Guidelines
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2021-03-30 04:00 GMT | Update On 2021-03-30 06:51 GMT
- Stage III and IVA disease are treated by CRT. The standard agent used is cisplatin.
- The most commonly used regimen is cisplatin 100 mg/m2 every 3 weeks concomitantly to RT. Weekly cisplatin (40 mg/m2/week) has also been shown to improve OS. The optimal cumulative total dose of concurrent cisplatin should be higher than 200 mg/m2.
- Concurrent nedaplatin was found to be non-inferior to concurrent cisplatin.
- Concurrent carboplatin is an available option but the evidence is conflicting.
- Intensification of the systemic treatment is needed for stage III-IVA non-keratinising NPC.
- ICT with cisplatin and gemcitabine followed by CRT for locally advanced NPC is associated with a benefit in RFS, OS and distant RFS, with more acute but not late toxicities versus CRT alone.
- The selection of patients to receive more ChT (post-chemotherapy) in addition to CRT in the form of either ICT or AC is a therapeutic area that is being explored in ongoing randomised controlled trials.
- In cases of persistent, high EBV DNA values after definitive treatment, a personalised approach with non-cross-resistant drugs or participation in a clinical trial is suggested.
- Small, local recurrences are potentially curable. The main therapeutic options include nasopharyngectomy, brachytherapy, radiosurgery, SRT, IMRT or a combination of surgery and RT, with or without concurrent ChT.
- Local recurrences not invading the carotid artery or extending intracranially are candidates for nasopharyngectomy; local recurrence, stage rT1-rT3 might benefit more from endoscopic nasopharyngectomy than IMRT.
- Lymphatic recurrences in the neck can be treated with neck dissection.
- In metastatic NPC, palliative ChT should be considered for patients with an adequate PS. A combination of platinum and gemcitabine is the first-line choice and improves OS.
- In patients with newly diagnosed, metastatic NPC, the addition of locoregional RT to systemic therapy improves locoregional control and ultimately OS.
- No standard second-line treatment exists. Active agents include paclitaxel, docetaxel, 5-FU, capecitabine, irinotecan, vinorelbine, ifosfamide, doxorubicin, oxaliplatin and cetuximab, which can be used as single agents or in selected combinations.
- Immunotherapy represents a promising strategy in this setting but its therapeutic positioning is still to be defined.
- CTL adoptive immunotherapy has demonstrated activity in highly pre-treated patients.
- Oligometastatic patients may achieve long-term survival after aggressive treatment, including chemotherapy, surgery or definitive RT to the metastases.
Personalised Medicine
- The first radiological imaging is suggested 3 months after completion of curative treatment. Sensitivity of MRI and PET are similar, whereas the specificity of PET is higher and so helps to differentiate between post-irradiation changes and recurrent tumours.
- Further follow-up for patients includes periodic examination of the nasopharynx and neck, cranial nerve function and evaluation of systemic complaints to identify distant metastasis. For T2-T4 tumours, MRI might be used on a 6-monthly basis for at least for the first 3 years after treatment.
- Plasma EBV DNA is a promising marker for the diagnosis of recurrence [II, B] and should be evaluated at least every year.
- Evaluation of thyroid function in patients who have received RT to the neck is recommended annually; pituitary function should also be evaluated according to signs/symptoms.
Reference:
"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up," is published in the journal journal Annals of Oncology.
DOI: https://www.annalsofoncology.org/article/S0923-7534(20)43210-7/fulltext
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd